Artivion Stock and Options Market: Artivion, Inc. (AORT) is experiencing high implied volatility in its options market, particularly with the Oct 17, 2025 $30.00 Put, indicating that investors expect significant price movement in the near future.
Analyst Sentiment and Earnings Estimates: Currently rated as a Zacks Rank #3 (Hold), Artivion has seen no upward revisions in earnings estimates over the last 60 days, with a consensus estimate decrease from 15 cents to 14 cents per share, suggesting cautious sentiment among analysts.
AI Investment Opportunities: The article discusses the potential for significant wealth creation in the next phase of AI, highlighting that early investors in companies like Nvidia have seen substantial gains, but warns that the rapid growth of the first wave of AI stocks may soon stabilize.
Zacks Investment Research Recommendations: Zacks offers insights into emerging AI companies poised for growth and provides a report on the "AI Boom 2.0," along with recommendations for stocks to consider in the coming month.
AORT
$46.07+Infinity%1D
Analyst Views on AORT
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 45.370
Low
40.00
Averages
51.71
High
58.00
Current: 45.370
Low
40.00
Averages
51.71
High
58.00
Ladenburg
Jeffrey Cohen
Neutral
maintain
$38 -> $40
2025-11-07
Reason
Ladenburg
Jeffrey Cohen
Price Target
$38 -> $40
2025-11-07
maintain
Neutral
Reason
Ladenburg analyst Jeffrey Cohen raised the firm's price target on Artivion to $40 from $38 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$40 -> $50
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$40 -> $50
2025-11-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Artivion to $50 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 revenue of $113.4M, +16% year-over-year, above its/consensus estimate of $112M/$110M. FY25 revenue guidance was raised, now $439M-$445M, and management remains confident about double-digit top-line growth.
Lake Street
Buy
maintain
$45 -> $55
2025-11-07
Reason
Lake Street
Price Target
$45 -> $55
2025-11-07
maintain
Buy
Reason
Lake Street raised the firm's price target on Artivion to $55 from $45 and keeps a Buy rating on the shares after Q3 revenue outperformed and management stated they remains confident in the ability to deliver double digit revenue growth while growing AEBITDA twice as fast in 2026.
Stifel
Rick Wise
Buy
maintain
$46 -> $55
2025-11-07
Reason
Stifel
Rick Wise
Price Target
$46 -> $55
2025-11-07
maintain
Buy
Reason
Stifel analyst Rick Wise raised the firm's price target on Artivion to $55 from $46 and keeps a Buy rating on the shares, noting that Q3 quarterly growth of about 16% year-over-year was "the fastest in several years." The firm says its 2026 revenue growth projection of $492M would be up about 11% from 2025.
About AORT
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
